TIDMPOLX
RNS Number : 4931Y
Polarean Imaging PLC
22 August 2018
Polarean Imaging Plc
("Polarean" or the "Company")
Half-year Report
Polarean Imaging plc (AIM: POLX), the medical-imaging technology
company, with a proprietary drug-device combination product for the
magnetic resonance imaging (MRI) market, announces its unaudited
interim results for the six months ended 30 June 2018.
Highlights
-- Successful admission to trading on AIM on 29 March 2018
-- GBP3m (gross) raised via a placing of 20,000,000 ordinary
shares at a placing price of 15p in March 2018
-- Delivery of Xenon Polarisers to Cincinnati Children's Hospital and University of Virginia
- University of Virginia Polariser to be used exclusively for Phase III Clinical Trials
-- Financial performance in-line with management expectations:
- Revenues of US $0.75m (H1 '17: US $0.17m);
- Operating gross margins, including grants, at over 70% margin
-- Net cash at 30 June 2018 of US $1.22m
Post-period end
-- Completion of successful Pilot Study prior to commencement of Phase III Trials
-- Phase III FDA Clinical Trials to commence shortly
-- US Patent Notice of Allowance received for polarization enhancing technology
-- Placing to raise GBP0.8m (gross) at 16p completed on 10 July 2018
Richard Hullihen, CEO of Polarean, commented: "The burden of
pulmonary disease in the USA is approximately US $150bn, with
pulmonary disease widespread and growing, affecting nearly 40
million Americans. Given the limitations of existing methods of
diagnosis and lung disease monitoring, we believe that there is a
significant unmet need for non-invasive, quantitative, and
cost-effective image-based diagnosis technology. We believe that
our unique medical drug-device combination utilizing 129Xe offers
the ideal solution for improving pulmonary disease diagnosis and we
are confident that this will be borne out during our Phase III
trials."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
Northland Capital Partners Limited Tel: +44 (0)20 3861
6625
David Hignell / Gerry Beaney / Jamie Spotswood
(Corporate Finance)
/ Rob Rees (Corporate Broking)
MC Services (European IR) Tel: +49 (0)89 210
2280
Raimund Gabriel
The Life Sciences Division (Financial Adviser)
Navid Malik, Director Mob: 07957 224 730
Alia Minhas, CEO Mob: 07590 696 057
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
Helen Cresswell 741 001
+44 (0)7841 917 679
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution functional
magnetic resonance imaging market.
CEO Statement
Introduction
The six month period ending 30 June 2018 has seen Polarean make
substantial progress towards its goal of undertaking and completing
our Phase III Clinical Trials for our medical drug-device
combination. This combination enables existing MRI systems to
achieve an improved level of pulmonary function imaging through the
use of hyperpolarised 129-Xenon gas (129Xe) as an imaging contrast
agent.
Our Phase III trials will be used to demonstrate that our
medical drug-device combination using 129Xe is capable of sharing
the same claims as the approved comparator 133-Xenon (133Xe) gas
scintigraphy. If the trials are successful the Company's ultimate
goal will be to submit a New Drug Application ("NDA") with the same
claim as 133Xe and seek FDA approval, allowing the launch of
clinically approved systems to be used "for the evaluation of
pulmonary function, for imaging the lungs" in early 2020.
The first half of the financial year was focussed on putting in
place the funding, contracts, agreed protocols, equipment and
supply agreements necessary to undertake our Phase III trials and
details of these milestones were outlined in our Final Results
statement announced in June. We expect the clinical trials to
commence shortly and the data collection for the trials is expected
to be completed during Q3 of 2019.
Admission to AIM
In March we successfully completed a GBP3m fundraising (before
expenses) and the listing of our shares on the AIM Market of the
London Stock Exchange. These funds provide us with the funding
security needed to complete our Phase III clinical trials. In
addition, the funds raised from our recent GBP0.8m (gross) placing
will further support the clinical trials and support improvements
to the Company's polarisers.
Results overview
Our financial performance, with sales being made on a
research-use-only basis to academic institutions in the US and
Europe, remains in-line with management expectations. Revenues for
the first half increased significantly from US $0.21m to US $0.75m,
with gross profits hitting US $0.47m (H1 '17: US $0.17m). Gross
operating margins remain at well over 50%. With a sizeable uplift
in Administrative Expenses, due in the main to fees associated with
our AIM admission, our overall loss before tax increased to GBP3.1m
from GBP1.4m in the same comparable period. Cash controls within
the business remain robust and as at 30 June 2018 we held US $1.22m
in net cash or cash equivalents.
The development of stronger recurring revenues are clearly
targeted for the business, assuming FDA approval is achieved. In
addition, the Company's longer term strategy is for our polarisers
to be operational beyond the academic research market that Polarean
currently serves.
Delivery of Xenon Polarisers
Whilst we seek clinical approval for our medical drug-device
combination we continue to expand our installed base of systems
through additional sales of research units to academic
institutions.
In May 2018 we announced the delivery of the latest model of our
Xenon polariser to the Center for Pulmonary Imaging Research at the
Cincinnati Children's Hospital Medical Center, with whom we hold a
Small Business Innovation Research grant awarded by the National
Heart, Lung and Blood Institute.
Cincinnati Children's, a non-profit academic medical center
globally-renowned for its paediatric teaching and research, is a
recognized leader in using hyperpolarized 129Xe for paediatric
pulmonary imaging through advanced imaging techniques.
Similarly in June 2018 we were pleased to announce the delivery
of our latest polariser to the University of Virginia Health System
(UVa), the site of one of our Phase III Clinical Trials. UVa has
been a key clinical collaborator with Polarean and, as a result of
this collaboration, the Department of Radiology & Medical
Imaging at UVa now has three latest-generation 129Xe Polarean
polarisers installed at their site with the latest system to be
used exclusively for our Phase III clinical trials.
We now have 15 Polarean Xenon polarisers in use at research
institutions across the US and Europe.
Post-period end events
Following the close of the first half we provided shareholders
with an update on additional progress made in preparation for the
imminent start of our clinical trials, as well as additional patent
protection and further funding support.
(i) Completion of successful Pilot Study prior to Phase III Clinical Trials
In last month's update we announced the completion of a Pilot
Study at one of our trial sites, which validated the study design
and the proposed analytical methods that will be used in the
trials. The successful conclusion of the pilot has provided us with
the confidence that the chosen methodology, agreed with the FDA, is
appropriate and should maximise the probability that both the
primary and secondary endpoints of our trials should clearly
demonstrate non-inferiority of 129Xe against 133Xe.
(ii) Phase III Clinical Trials scheduled to start this month and
due to complete in Q3 2019
In addition, we were also able to announce that our 'head to
head' non-inferiority trials against 133Xe scintigraphy, a 40 year
old nuclear medicine technique using radioactive (133) Xe and gamma
cameras, will commence very shortly. We expect to provide an
announcement to investors as soon as the trial starts.
The Phase III Trials will evaluate two patient populations -
candidate patients for lung lobe resection, and candidates for lung
transplant procedures - and will encompass a total of 80 patients,
across two sites: the University of Virginia and Duke University.
We currently expect data collection for the Phase III Trials to
complete during Q3 of 2019 and if successful, we will submit our
NDA with the same claim as 133Xe soon after.
(iii) US Patent Notice of Allowance received
We also were pleased to announce receipt of a Notice of
Allowance for the U.S. Patent covering "Hyperpolarized Noble Gas
Production Systems with Nanocluster Suppression, Detection, and/or
Filtering and Related Methods and Devices" to which we have the
exclusive rights. This patent, together with our know-how, has led
to increasing levels of polarisation for our MRI
gas-hyperpolarisation platform and is key to advancing image
quality, exploring new applications and increasing the overall
efficiency of our systems. This patent adds to our IP portfolio of
29 patents with a broad area of coverage around our technology and
extending into 2034.
(iv) Placing to raise GBP0.8m (gross) at 16p completed
On the 10 July we announced the successful completion of a
Placing to raise an additional GBP0.8 million at a price of 16
pence (before expenses) in response to strong demand from
institutional and EIS/VCT investors. We are very pleased with
support shown by new and existing shareholders and these additional
funds will further support our clinical trials in the US and the
improvements we continue to make to our polarisers.
(v) Delivery of Polariser to Duke for Clinical Trial
in August 2018 we were pleased to announce the delivery of our
latest polariser to the Duke Unversity (Duke), the site of one of
our Phase III Clinical Trials. Duke has been a key technology and
clinical collaborator with Polarean and, as a result of this
collaboration, the Department of Radiology at Duke now has three
129Xe Polarean polarisers installed at their site with the latest
system to be used exclusively for our Phase III clinical
trials.
Outlook
I am excited that we will shortly start our FDA Phase III
clinical trials and I look forward to updating shareholders once it
commences and with our progress.
The burden of pulmonary disease in the USA is approximately US
$150bn, with pulmonary disease widespread and growing, affecting
nearly 40 million Americans. Given the limitations of existing
methods of diagnosis and lung disease monitoring, we believe that
there is a significant unmet need for non-invasive, quantitative,
and cost-effective image-based diagnosis technology. We believe
that our unique medical drug-device combination utilizing 129Xe
offers the ideal solution for improving pulmonary disease diagnosis
and we are confident that this will be borne out during our Phase
III trials.
Richard Hullihen
Chief Executive Officer
22 August 2018
Consolidated unaudited statement of comprehensive income
for the six months ended 30 June 2018
Unaudited Unaudited Audited
Note 6 months 6 months 12 months
ended 30.6.18 ended 30.6.17 ended 31.12.17
US$ US$ US$
Revenue 1,026,926 205,085 1,237,163
Cost of sales (279,455) (33,712) (297,215)
--------------- --------------- ----------------
Gross profit 747,471 171,373 939,948
Administrative expenses (3,106,922) (1,502,079) (4,051,000)
Depreciation (4,489) (2,885) (7,478)
Amortisation (308,426) (2,300) (361,746)
Selling and distribution expenses (20,998) (15,474) (28,752)
Share based payment expense (87,400) (402,007) (414,866)
--------------- --------------- ----------------
Loss from operations (2,780,764) (1,753,372) (3,923,894)
Finance Charges (52,654) (7,160) (34,056)
Finance Income 27 - 129
--------------- --------------- ----------------
Loss on ordinary activities
before taxation 3 (2,833,391) (1,760,532) (3,957,821)
Taxation - - -
--------------- --------------- ----------------
Loss and total other comprehensive
expense (2,833,391) (1,760,532) (3,957,821)
Basic and fully diluted loss
per share (US$) 3 (0.057) (0.062) (0.139)
POLAREAN IMAGING PLC
Consolidated unaudited statement of financial position
As at 30 June 2018
Unaudited Unaudited Audited
As at 30.6.18 As at 30.6.17 As at 31.12.17
US$ US$ US$
Assets Note
Non-current assets
Property, plant and equipment 23,403 16,398 21,341
Intangible assets 4,352,824 5,020,696 4,661,250
Trade and other receivables 12,536 5,539 12,539
-------------- -------------- ---------------
4,388,763 5,042,633 4,695,130
Current assets
Inventories 1,069,342 392,932 649,860
Trade and other receivables 1,148,306 22,209 488,861
Cash and cash equivalents 1,374,866 1,712,073 960,217
-------------- -------------- ---------------
3,592,514 2,127,214 2,098,938
-------------- -------------- ---------------
Total assets 7,981,277 7,169,847 6,794,068
-------------- -------------- ---------------
Equity
Share capital 4 36,396 23,291 23,291
Share premium 6,432,812 1,808,587 1,448,037
Group reorganisation reserve 7,813,337 7,813,337 7,813,337
Other equity - - 87,305
Share based payment reserve 913,945 813,686 826,545
Retained losses (9,591,499) (4,560,819) (6,758,108)
-------------- -------------- ---------------
Total equity 5,604,991 5,898,082 3,440,407
Liabilities
Non-current liabilities
Deferred revenue - 36,152 -
Contingent consideration 316,000 316,000 316,000
-------------- -------------- ---------------
316,000 352,152 316,000
Current liabilities
Trade and other payables 1,908,079 521,719 1,906,376
Borrowings 5 149,878 379,541 1,104,723
Deferred revenue 2,329 18,353 26,562
-------------- -------------- ---------------
2,060,286 919,613 3,037,661
-------------- -------------- ---------------
Total equity and liabilities 7,981,277 7,169,847 6,794,068
-------------- -------------- ---------------
Consolidated unaudited statement of changes in equity
As at 30 June 2018
Other Share Retained
equity based earnings
Share Share Group payment
capital premium re-organisation reserve Total equity
--------- --------- ------------------ -------- --------- ------------- --------------
Balance as at 31
December
2016 (audited) 1 - 1,976,367 - 238,172 (2,800,287) (585,747)
--------- --------- ------------------ -------- --------- ------------- --------------
Loss and total
comprehensive
income for the
year - - - - - (3,957,821) (3,957,821)
Transaction with
owners
Issue of shares 2,970 1,982,094 - - - - 1,985,064
Share issue
costs - (534,057) - - 173,507 - (360,550)
Share-based
payments - - - - 414,866 - 414,866
Group
re-organisation 20,320 - 5,836,970 - - - 5,857,290
Convertible
loans - - - 87,305 - - 87,305
Balance as at 31
December
2017 (audited) 23,291 1,448,037 7,813,337 87,305 826,545 (6,758,108) 3,440,407
Loss and total
comprehensive
income for the
period - - - - - (2,833,391) (2,833,391)
Transaction with
owners
Issue of shares 13,105 5,124,897 - (87,305) - - 5,050,697
Share issue
costs - (140,122) - - - - (140,122)
Share-based
payments - - - - 87,400 - 87,400
Balance as at 30
June
2018
(unaudited) 36,396 6,432,812 7,813,337 - 913,945 (9,591,499) 5,604,991
========= ========= ================== ======== ========= ============= ==============
Consolidated unaudited cash flow statement
for the six months ended 30 June 2018
Unaudited Unaudited Audited
6 months 6 months 12 months
ended 30.6.18 ended 30.6.17 ended
US$ US$ 31.12.17
US$
Cashflows from operating activities
Loss for the period before taxation (2,833,391) (1,760,532) (3,957,821)
Adjustments for non-cash/non-operating
items:
Depreciation of plant and equipment 4,489 2,884 7,478
Amortisation of intangible assets 308,426 2,300 361,746
Increase in provision for contingent - - -
consideration
Share based compensation 87,400 402,007 414,866
Interest paid 52,654 2,160 34,056
Interest received (27) - (129)
Write off of share issuance costs - 156,953 -
--------------- --------------- ------------
(2,380,449) (1,194,228) (3,139,804)
Changes in working capital:
(Increase) in inventories (419,482) (71,271) (328,199)
(Increase) in trade and other
receivables (659,448) (7,753) (440,931)
Increase/(decrease) in trade and
other payables 10,026 (12,121) 1,343,861
Decrease in deferred revenue (24,233) (22,675) (50,618)
--------------- --------------- ------------
Taxation - - -
--------------- --------------- ------------
Net cash flows used from operating
activities (3,473,586) (1,308,048) (2,615,691)
--------------- --------------- ------------
Investing activities
Purchase of plant and equipment (6,551) (7,298) (16,834)
--------------- --------------- ------------
Net cash used in investing activities (6,551) (7,298) (16,834)
Financing activities
(Repayment of) proceeds from borrowings (116,126) 275,000 1,047,014
Issue of shares 4,063,539 2,656,732 2,481,808
Interest paid (52,654) (2,160) (34,056)
Interest received 27 - 129
--------------- --------------- ------------
Net cash from financing activities 3,894,786 2,929,572 3,494,895
Net increase in cash and equivalents 414,649 1,614,226 862,370
Cash and equivalents at beginning
of period 960,217 97,847 97,847
Cash and equivalents at end of
period 1,374,866 1,712,073 960,217
NOTES TO THE INTERIM ACCOUNTS
1. Basis of preparation
The accounting policies adopted are consistent with those of the
previous financial year ended 31 December 2017.
This interim consolidated financial information for the six
months ended 30 June 2018 has been prepared in accordance with AIM
rule 18, 'Half yearly reports and accounts'. This interim
consolidated financial information is not the group's statutory
financial statements within the meaning of section 434 of the
Companies Act 2006 (and information as required by section 435 of
the Companies Act 2006) and should be read in conjunction with the
annual financial statements for the year ended 31 December 2017,
which have been prepared in accordance with International Financial
Reporting Standards (IFRS) and have been delivered to the Registrar
of Companies. The auditors have reported on those accounts; their
report was unqualified, did not include references to any matters
to which the auditors drew attention by way of emphasis of matter
without qualifying their report and did not contain statements
under section 498(2) or (3) of the Companies Act 2006.
The interim consolidated financial information for the six
months ended 30 June 2018 is unaudited. In the opinion of the
Directors, the interim consolidated financial information presents
fairly the financial position, and results from operations and cash
flows for the period. Comparative numbers for the six months ended
30 June 2017 are also unaudited.
This interim consolidated financial information is presented in
US Dollars ($).
IFRS15 - Accounting Policies and Transition
The directors have reviewed the way that the group accounts for
revenues from contracts with customers and has adopted the new
reporting standard on revenue recognition, IFRS 15. Following that
review, the directors did not consider it necessary to change the
group's accounting policies with respect to revenue recognition.
There have been no changes to recognition or measurement of revenue
or to the consolidated statements of comprehensive income or
financial position as a consequence of adopting IFRS15.
2. Going concern
The interim consolidated financial information for the six
months ended 30 June 2018 have been prepared on the going concern
basis.
The Directors consider the going concern basis of preparation to
be appropriate in preparing the financial statements. In
considering the appropriateness of this basis of preparation, the
Directors have received the Group's working capital forecasts for a
minimum of 12 months from the date of the approval of this
financial information. Based on their consideration the Directors
have reasonable expectation that the Group has adequate resources
to continue for the foreseeable future and that carrying values of
intangible assets are supported. Thus, they continue to adopt the
going concern basis of accounting in preparing this financial
information.
3. Loss per share
On 16 February 18, the Company sub-divided its share capital on
the basis of 26.71999:1. The loss per share has been restated for
the subdivision in the comparatives presented for the six months
ended 30 June 17 and the year ended 31 December 17.
The basic and diluted loss per share for the period ended 30
June 2018 was US$0.057 (2017: US$0.062) The calculation of loss per
share is based on the loss of US$2,833,391 for the period ended 30
June 2018 (2017: loss of US$1,760,532) and the weighted average
number of shares in issue during the period for calculating the
basic profit per share of 49,432,227 shares (2017: 28,497,296).
4. Called up share capital
Unaudited Unaudited Audited
30.6.18 30.6.17 31.12.17
US$ US$ US$
Allotted, issued and fully paid
Ordinary Shares 36,396 23,291 23,291
---------- ---------- ---------
The number of shares in issue was as follows: Number of
shares
Balance at 1 January 2017 1
Effect of share split 99
Issued during the period 1,813,903
-----------
Balance at 30 June 2017 1,814,003
Issued during the period -
-----------
Balance at 31 December 2017 1,814,003
Effect of share split 46,656,158
Issued during the period 24,939,303
-----------
Balance at 30 June 2018 73,409,464
-----------
On 16 February 18, the Company sub-divided its existing share
capital on the basis of 26.71999:1, resulting in the issue of
46,656,158 ordinary shares. The Company then issued 24,939,303 new
ordinary shares on the 29 March, comprising of 20,000,000 shares
issued as part of the admission to AIM and 4,939,303 shares issued
repay a convertible loan and accrued interest.
5. Borrowings
Unaudited Unaudited Audited
30.6.18 30.6.17 31.12.17
US$ US$ US$
Related Party Loans 7,936 104,451 47,086
Notes Payable - 275,000 265,750
Bank Overdraft 141,942 - -
Convertible Loan Notes - - 791,887
---------- ---------- ----------
Total 149,878 379,541 1,104,723
---------- ---------- ----------
In the interim period to June 2018, an unsecured convertible
loan note that was issued for a principal amount of US$903,000
(GBP647,147) was converted with accrued interest, into 4,939,303
ordinary shares in the Company at a conversion price equal to 90
per cent. of the issue price of the ordinary shares upon
admission.
During the interim period, an unsecured loan note for a
principal amount of US$250,000 was repaid. The conditions of the
loan note detailed the Group was to receive the initial 50 per cent
of the loan upon the completion of the loan agreement. Upon the
completion of the mid-term project report, the Group will receive
40 per cent of the loan, while the remaining 10 per cent will be
received upon completion of the project. At the point of
settlement, the Group had received 50 per cent of the principal in
accordance with the conditions in the agreement.
An unsecured promissory note that was issued in June 17 for a
principal amount of US$150,000, with an interest rate of 6 per cent
per annum, was settled in full with all outstanding interest in
April 2018.
6. Share based payments
Share Options
The Company grants share options as its discretion to Directors,
management and employees. These are accounted for as equity settled
transactions. Should the options remain unexercised after a period
of ten years from the date of grant the options will expire unless
an extension is agreed to by the board. Options are exercisable at
a price equal to the Company's quoted market price on the date of
grant or an exercise price to be determined by the board.
Details of share options granted, exercised, lapsed and
outstanding at the year-end are as follows:
Number of Weighted average
share options exercise price(US$)
Outstanding at 1 January 2018 5,156,960 0.02
Granted during the period 9,629,868 0.20
Outstanding at 30 June 2018 14,786,828 0.13
-------------------------------- --------------- ---------------------
Exercisable at 30 June 2018 5,073,980 0.04
-------------------------------- --------------- ---------------------
The opening balance of share options as at 1 January 18 has been
adjusted to reflect the subdivision of share capital on a basis of
26.719999: 1.
The fair value of options granted has been calculated using the
Black Scholes model which has given rise to fair values per share
of US$0.09. This is based on risk-free rates of 1.14% and
volatility of 40.84%.
The weighted average contractual life of the share options
outstanding at the reporting date is 9.67 years.
Share Warrants
The Company grants share warrants at its discretion to
Directors, management, employees, advisors and lenders. These are
accounted for as equity settled transactions. Terms of warrants
vary from agreement to agreement.
Details for the warrants granted, exercised, lapsed and
outstanding at the period ending 30 June 2018 are as follows:
Number Weighted average
of share exercise price
warrants (US$)
Outstanding at 1 January 2018 9,065,428 0.16
Lapsed during the period (2,618,373) 0.34
Granted during the period 253,400 0.20
Outstanding at 30 June 2018 6,700,455 0.08
-------------------------------- ------------ -----------------
Exercisable at 30 June 2018 6,229,709 0.07
-------------------------------- ------------ -----------------
The opening balance of share warrants as at 1 January 18 has
been adjusted to reflect the subdivision of share capital on a
basis of 26.719999: 1
The weighted average contractual life of the share options
outstanding at the reporting date is 4.81 years.
7. Subsequent events
On 10 July 2018, the Company announced it had raised a total of
GBP0.8million (before expenses) via the placing of total of
5,000,000 ordinary shares at a price of 16p per share with new and
existing investors. The net proceeds of the placing will be used to
further support the FDA Phase III clinical trials in the US and
further support improvements on the Company's polarisers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IR BCGDISXDBGIB
(END) Dow Jones Newswires
August 22, 2018 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024